Prestige Biologics Co Ltd

Prestige Biologics has a debt-to-equity ratio of 0.68 and a current ratio of 0.4, indicating moderate leverage and weak short-term liquidity. The company's negative operating and free cash flows (-18.3 billion KRW and -20.0 billion KRW, respectively) suggest ongoing cash burn, with capital expenditures of -5.7 billion KRW further straining liquidity. The company's return on equity (-20.3%) and return on assets (-10.2%) are significantly below the industry's median profitability metrics, reflecting poor capital efficiency and operational performance. These metrics suggest the company is underperforming relative to its peers in generating returns for shareholders and asset utilization. Prestige Biologics does not disclose segment or geographic revenue breakdowns in the provided data, so no conclusions can be drawn about revenue concentration or geographic exposure. The absence of segment data limits visibility into the company's diversification and risk profile. The company's revenue of 12.5 billion KRW is declining, with no outlook data provided to quantify the rate of change. The negative net income of -27.5 billion KRW and operating income of -33.7 billion KRW indicate a deepening loss position, with no clear path to profitability in the near term. The risk assessment highlights medium liquidity risk and low dilution risk, but the key flag of negative net cash after subtracting total debt signals significant financial stress. No dilution sources are disclosed in the provided data, and no adjustments are applied to the valuation metrics. No recent events, filings, or transcripts are provided in the input data to inform the company's current strategic or operational developments.